Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

NCT00091793 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: AMG 162
DRUG: Placebo

Sponsor

Amgen